Literature DB >> 12138332

Effect of Micafungin (FK463) on Candida albicans adherence to epithelial cells.

Margarete Borg-von Zepelin1, Karen Zaschke, Uwe Gross, Michel Monod, Frank-Michael C Müller.   

Abstract

BACKGROUND: Adherence is considered a major virulence trait of Candida albicans. FK463 is a new investigational intravenous antifungal of the 'candin family' with potent in vitro and in vivo activity against Candida spp.
OBJECTIVE: The aim of the present study was to investigate the effect of Micafungin (FK463) on Candida adherence to epithelial cells of azole-sensitive and azole-resistant C. albicans isolates.
METHODS: An in vitro assay using microtest plate technology and fluorescence measurement was developed to compare the adherence of C. albicans SC5314 and of paired C. albicans isolates to epithelial cells in the presence and in the absence of FK463.
RESULTS: FK463 showed a marked inhibitory effect on the adherence of C. albicans SC5314. The addition of FK463 reduced the adherence of C. albicans SC5314 to 90% of the value of control without drug. A dose-dependent adherence inhibition was observed with FK463 in the range of 10-0.015 microg ml(-1). The comparison of paired C. albicans isolates, either a fluconazole-susceptible and a fluconazole-resistant isolate of one patient, revealed no significant difference in the adherence behavior between azole-susceptible and azole-resistant.
CONCLUSION: Micafungin (FK463) has the capacity to reduce adherence of C. albicans azole-susceptible and azole-resistant strains to epithelial cells. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12138332     DOI: 10.1159/000064921

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  6 in total

Review 1.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 2.  Candida infections of the genitourinary tract.

Authors:  Jacqueline M Achkar; Bettina C Fries
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 3.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.

Authors:  Sarah A Cross; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.

Authors:  Katherine T Nguyen; Philip Ta; Bich Thu Hoang; Shaoji Cheng; Binghua Hao; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

6.  Review of the pharmacology and clinical studies of micafungin.

Authors:  Alison M Bormann; Vicki A Morrison
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.